1-832-868-1888
order@swbio.com
Catalog Number: |
24651 |
other_names: | Leucine-rich, glioma inactivated 4 |
Amount: |
100μg |
calculated_mw: | |
host_species: | Rabbit |
Price: |
$319 |
Swiss-Prot No: |
Swiss-Prot:Q8N135 |
Form of Antibody: |
Supplied in PBS containing 0.02% sodium azide. |
Storage/Stability: |
|
Immunogen: |
Raised against a 14 amino acid peptide from near the center of human LGI4. |
Purification: |
Affinity chromatography purified via peptide column |
Specificity/Sensitivity: |
Two isoforms of LGI4 are known to exist; this LGI4 antibody will recognize only the larger form. This LGI4 antibody is predicted to be specific to LGI4 and not recognize other LGI proteins. |
Applications: |
ELISA WB |
Background: |
The leucine-rich, glioma inactivated gene 4 (LGI4) is a member of the LGI family in which LGI1 is the exemplar. The LGI family consists of four of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 has been identified as a candidate tumor suppressor gene for glioma and plays a role in autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Despite its high homology with LGI1 and similar pattern of expression, mutations in LGI4 have not been found to be associated with ADTLE. However, the LGI4 gene is located in a region linked to benign familial infantile convulsions. Further study revealed that a GC-to-AT polymorphism was correlated with childhood absence epilepsy. Other studies showed that decreasing LGI4 expression in cultured cells inhibits myelination, indicating that LGI4 may play a role in neural development. |
References: |
|
appl_detail: |
|
QUICK LINKS
Unique Antibodies Cancer/Apoptosis antibody Tag Antibody Neuroscience antibody MAP kinase antibody Secondary AntibodyCONTACT US
1-832-868-1888 order@swbio.comGET IN TOUCH